DP-9024 (Deciphera Pharma)

DP-9024 (Deciphera Pharma): sourced facts only. name: "DP-9024 was designed as a selective and potent modulator of PERK and GCN2." [DOI:10.1158/1538-7445.am2023-1640]; target: "DP-9024 was designed as a selective and potent modulator of PERK and GCN2." [DOI:10.1158/1538-7445.am2023-1640]; developer: "1Deciphera Pharmaceuticals, LLC, Lawrence, KS." [DOI:10.1158/1538-7445.am2023-1640]; modality: "DP-9024, an investigational small molecule modulator of the Integrated Stress Response kinase PERK, causes B-cell cancer growth inhibition as single agent and in combination with standard-of-care agents" [DOI:10.1158/1538-7445.am2023-1640]; stage: "Oral dosing of DP-9024 in MM xenograft models induced ATF4, and combination efficacy was observed in MM and B-cell lymphoma xenografts in combination with FDA approved agents in vivo." [DOI:10.1158/1538-7445.am2023-1640]